Vitamin D Supplementarion in Pregnant Women at Risk and COVID-19

Summary

Participation Requirements

Description

Researchers propose a randomized, non-blinded clinical trial in pregnant women recruited at the obstetrics and gynecology service of the Virgen de las Nieves University Hospital Granada during the appointment of the first gynecological control visit (weeks 10-12 of pregnancy). The woman participatin...

Researchers propose a randomized, non-blinded clinical trial in pregnant women recruited at the obstetrics and gynecology service of the Virgen de las Nieves University Hospital Granada during the appointment of the first gynecological control visit (weeks 10-12 of pregnancy). The woman participating in the study will be assigned to two randomized follow-up groups, intervention group that will be supplied with 2.000 IU of vitamin D and control group with 400 IU of vitamin D, in turn they will be allocated to a risk group and healthy group. Participants will take the supplementation from 10-12 weeks of gestation to delivery. The frequency of gybecological visits will coincide with their routine prenatal visits: weeks 10-12, weeks 20-24 and weeks 34-35 of gestation. During the entire duration of the study, pregnant women will be in touch with the health professionals through routine hospital controls. The present study was approved by the Ethics Commitee CEIM/CEI of Granada, Spain.

Tracking Information